Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy
- Citation:
- Blood vol 134 (Supplement 1) abstract 1366
- Meeting Instance:
- ASH 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Leukemia
- Sec. Committees:
- Older Adult
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA189823, U24CA196171; U10CA180820 (ECOG-ACRIN); U10CA180888, UG1CA233270 (SWOG)
- Corr. Author:
- Authors:
- Geoffrey L. Uy Vivien Yin Heidi Klepin Shira Dinner Anthony Jaslowski Steven A. Strickland Jane L. Liesveld John C. Byrd Richard M. Stone
- Networks:
- LAPS-IL036, LAPS-MA036, LAPS-MO011, NC002, OH070, TN008, WINCORP
- Study
- Alliance-A041701
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2/3
- Keywords: